» Articles » PMID: 21272002

The Tyrosine Phosphatase Shp-2 Interacts with the Dopamine D(1) Receptor and Triggers D(1) -mediated Erk Signaling in Striatal Neurons

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2011 Jan 29
PMID 21272002
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

We report a novel mechanism for dopamine D(1) receptor (D(1) R)-mediated extracellular signal-regulated kinases (Erk) activation in rat striatum. Erk signaling depends on phosphorylation and dephosphorylation events mediated by specific kinases and phosphatases. The tyrosine phosphatase Shp-2, that is required for Erk activation by tyrosine kinase receptors, has been recently shown to regulate signaling downstream of few G protein-coupled receptors. We show that the D(1) R interacts with Shp-2, that D(1) R stimulation results in Shp-2 tyrosine phosphorylation and activation in primary striatal neuronal cultures and that D(1) R/Shp-2 interaction is required for transmitting D(1) R-dependent signaling to Erk1/2 activation. D(1) R-mediated Erk1/2 phosphorylation in cultured striatal neurons is in fact abolished by over-expression of the inactive Shp-2(C/S) mutant and by small interfering RNA-induced Shp-2 silencing. Moreover, by using selective inhibitors we show that both D(1) R-induced Shp-2 activation and Erk1/2 phosphorylation are dependent on the cyclic AMP/protein kinase A pathway and require Src. These results, which were substantiated also in transfected human embryonic kidney 293 cells, provide a novel mechanism by which to converge D(1) R signaling to the Erk pathway and suggest that Shp-2 or the D(1) R/Shp-2 interface could represent a potential drug target for disorders of dopamine transmission involving malfunctioning of D(1) R signaling.

Citing Articles

Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.

de Bartolomeis A, Ciccarelli M, De Simone G, Mazza B, Barone A, Vellucci L Int J Mol Sci. 2023; 24(6).

PMID: 36983018 PMC: 10051989. DOI: 10.3390/ijms24065945.


G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2.

Bono F, Tomasoni Z, Mutti V, Sbrini G, Kumar R, Longhena F Biomolecules. 2023; 13(3).

PMID: 36979407 PMC: 10046256. DOI: 10.3390/biom13030473.


The Signaling and Pharmacology of the Dopamine D1 Receptor.

Jones-Tabah J, Mohammad H, Paulus E, Clarke P, Hebert T Front Cell Neurosci. 2022; 15:806618.

PMID: 35110997 PMC: 8801442. DOI: 10.3389/fncel.2021.806618.


The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.

Wu N, Wan Y, Song L, Qi C, Liu Z, Gan J Neuropsychiatr Dis Treat. 2018; 14:1779-1786.

PMID: 30013350 PMC: 6038854. DOI: 10.2147/NDT.S162562.


Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia.

Solis O, Moratalla R J Neural Transm (Vienna). 2018; 125(8):1187-1194.

PMID: 29417335 DOI: 10.1007/s00702-018-1852-x.